Medigen Vaccine Biologics Corp. (MVC) a Taiwan based company to collaborate with the U.S. National Institutes of Health (NIH) to develop a vaccine against COVID-19 coronavirus.
The company signed an agreement with the NIH the previous day allowing it to obtain the candidate vaccine virus, according to MVC.
The company signed an agreement with the NIH the previous day allowing it to obtain the candidate vaccine virus, according to MVC.
Additionally, all related material developed by the U.S. health institution for potential use in humans to jump-start candidate vaccine development for COVID-19 in Taiwan
The company said it will soon start animal testing in Taiwan that will be use to assess and if successful it will generate vaccines for humans.
MVC is a biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC has established a foothold in Taiwan and given priority to developing innovative pharmaceutical products for unmet medical needs.
MVC is a biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC has established a foothold in Taiwan and given priority to developing innovative pharmaceutical products for unmet medical needs.
No comments:
Post a Comment